Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Radoslaw Magierski & Tomasz Sobow. (2016) Serotonergic drugs for the treatment of neuropsychiatric symptoms in dementia. Expert Review of Neurotherapeutics 16:4, pages 375-387.
Read now
Read now
Ricardo P. Garay, Michel Bourin, Evelyne de Paillette, Ludovic Samalin, Ahcène Hameg & Pierre-Michel Llorca. (2016) Potential serotonergic agents for the treatment of schizophrenia. Expert Opinion on Investigational Drugs 25:2, pages 159-170.
Read now
Read now
Articles from other publishers (13)
Ramakrishna Nirogi, Pradeep Jayarajan, Anil Shinde, Abdul Rasheed Mohammed, Venkata Ramalingayya Grandhi, Vijay Benade, Vinod Kumar Goyal, Renny Abraham, Venkat Jasti & Jeffrey Cummings. (2023) Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders. Biomolecules 13:2, pages 309.
Crossref
Crossref
Jitendra Kumar Sinha, Punya Sachdeva, Faizan Ahmad, Jasmine Sarkar, Raafiah Izhar, Ayesha Rahman & Shampa Ghosh. 2023. Cognizance of Schizophrenia:: A Profound Insight into the Psyche. Cognizance of Schizophrenia:: A Profound Insight into the Psyche
149
179
.
Charlotte Uldahl Jansen & Katrine M. Qvortrup. 2022. Serotonin and the CNS - New Developments in Pharmacology and Therapeutics. Serotonin and the CNS - New Developments in Pharmacology and Therapeutics.
David M. Taylor, Thomas R. E. Barnes & Allan H. Young. 2021. The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines in Psychiatry
601
677
.
Elahe Zarini-Gakiye, Javad Amini, Nima Sanadgol, Gholamhassan Vaezi & Kazem Parivar. (2020) Recent Updates in the Alzheimer’s Disease Etiopathology and Possible Treatment Approaches: A Narrative Review of Current Clinical Trials. Current Molecular Pharmacology 13:4, pages 273-294.
Crossref
Crossref
Magdalena Kotańska, Klaudia Lustyk, Adam Bucki, Monika Marcinkowska, Joanna Śniecikowska & Marcin Kołaczkowski. (2018) Idalopirdine, a selective 5-HT6 receptor antagonist, reduces food intake and body weight in a model of excessive eating. Metabolic Brain Disease 33:3, pages 733-740.
Crossref
Crossref
Orkid Coskuner-Weber & Vladimir Uversky. (2018) Insights into the Molecular Mechanisms of Alzheimer’s and Parkinson’s Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology. International Journal of Molecular Sciences 19:2, pages 336.
Crossref
Crossref
Adam Bucki, Monika Marcinkowska, Joanna Śniecikowska, Krzysztof Więckowski, Maciej Pawłowski, Monika Głuch-Lutwin, Anna Gryboś, Agata Siwek, Karolina Pytka, Magdalena Jastrzębska-Więsek, Anna Partyka, Anna Wesołowska, Paweł Mierzejewski & Marcin Kołaczkowski. (2017)
Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1
H
-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity
. Journal of Medicinal Chemistry 60:17, pages 7483-7501.
Crossref
Crossref
Jin Ri Hong, Hyunah Choo & Ghilsoo Nam. (2017) Neuropathic pain-alleviating effects of pyrazole-conjugated arylsulfonamides as 5-HT6 receptor antagonists. Bioorganic & Medicinal Chemistry Letters 27:17, pages 4146-4149.
Crossref
Crossref
Alexandre V. Ivachtchenko, Ilya Okun, Vladimir Aladinskiy, Yan Ivanenkov, Angela Koryakova, Ruben Karapetyan, Oleg Mitkin, Ramiz Salimov & Andrey Ivashchenko. (2017) AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation. Journal of Alzheimer's Disease 58:4, pages 1043-1063.
Crossref
Crossref
Margarita MorozovaDenis BurminskiyGeorge RupchevTaissia LepilkinaSergey PotaninAllan BeniashviliYan LavrovskyNatalia VostokovaAlexander Ivaschenko. (2017) 5-HT6 Receptor Antagonist as an Adjunct Treatment Targeting Residual Symptoms in Patients With Schizophrenia. Journal of Clinical Psychopharmacology 37:2, pages 169-175.
Crossref
Crossref
Ramakrishna Nirogi, Anil Shinde, Rama Sastry Kambhampati, Abdul Rasheed Mohammed, Sangram Keshari Saraf, Rajesh kumar Badange, Thrinath Reddy Bandyala, Venugopalarao Bhatta, Kumar Bojja, Veena Reballi, Ramkumar Subramanian, Vijay Benade, Raghava Choudary Palacharla, Gopinadh Bhyrapuneni, Pradeep Jayarajan, Vinod Goyal & Venkat Jasti. (2017)
Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1
H
-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT
6
) Receptor Antagonist for Potential Treatment of Alzheimer’s Disease
. Journal of Medicinal Chemistry 60:5, pages 1843-1859.
Crossref
Crossref
Katarzyna Grychowska, Grzegorz Satała, Tomasz Kos, Anna Partyka, Evelina Colacino, Severine Chaumont-Dubel, Xavier Bantreil, Anna Wesołowska, Maciej Pawłowski, Jean Martinez, Philippe Marin, Gilles Subra, Andrzej J. Bojarski, Frédéric Lamaty, Piotr Popik & Paweł Zajdel. (2016)
Novel 1
H
-Pyrrolo[3,2-
c
]quinoline Based 5-HT
6
Receptor Antagonists with Potential Application for the Treatment of Cognitive Disorders Associated with Alzheimer’s Disease
. ACS Chemical Neuroscience 7:7, pages 972-983.
Crossref
Crossref